Introduction
The ability of tumors to grow beyond a few cubic millimeters in volume depends on the formation of new blood vessels within the microenvironment of the tumors (Carmeliet and Jain, 2000; Kerbel, 2000; Yancopoulos et al., 2000; Ferrara, 2002b) . This angiogenic process is triggered by several key growth factors that are secreted by the tumor. The growth factors not only bind their receptors on endothelial cells and stimulate their proliferation initiating new blood vessel formation but also bind receptors on accessory cells such as pericytes that maintain vessel integrity (Helmlinger et al., 1997; Holash et al., 1999; Carmeliet and Jain, 2000; Kerbel, 2000; Yancopoulos et al., 2000; Ferrara, 2002b) . Among the most studied growth factors are vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Several studies have demonstrated the participation of these two growth factors in the angiogenic process, with VEGF playing a key role mainly in the initiation of the formation of new blood vessels and PDGF being involved in the maintenance of these vessels (Dvorak et al., 1999; Eriksson and Alitalo, 1999; Ferrara, 1999; Dvorak, 2002; Bergers et al., 2003) . This observation prompted an interest in designing strategies to suppress the functions of VEGF and PDGF, with the ultimate goal of inhibiting angiogenesis and starving tumors. The approaches that have been taken were based on targeting the biochemical steps involved in the mechanism of action of these growth factors. These include inhibiting the binding of VEGF and PDGF to their respective receptors by using antibodies against the growth factors. One of these, Avastin, which targets VEGF, has recently been approved for clinical use in patients with metastatic colorectal cancer (Ferrara, 2002a; Zhang et al., 2002) . Another approach has involved the development of inhibitors of the tyrosine kinase activities of the PDGF and VEGF receptors, resulting in suppression of the downstream signal transduction pathways triggered by these growth factors (Kerbel, 2000; Laird et al., 2000; Morin, 2000; Wedge et al., 2000; Jain, 2002; Miao et al., 2002) . Most of these agents mimic the structure of ATP and some are potent antitumor agents that are presently in clinical trials. However, none have been approved yet by the FDA.
The approval by the FDA of Avastin, which increases by 5 months the median survival of patients with metastatic colorectal cancer, further validates targeting angiogenic processes as a strategy to treat cancer (Ferrara, 2002a) . However, much more needs to be done to fully exploit this approach. For example, in other clinical trials, Avastin failed to prolong the lives of patients with metastatic breast cancer. One possible explanation for this inconsistent activity is that advanced metastatic breast cancer may circumvent anti-VEGF angiogenesis therapy by means of other growth factors. Indeed, support for this suggestion comes from preclinical studies showing that early breast cancer secretes mainly VEGF, whereas advanced breast cancer secretes additional growth factors (Relf et al., 1997) . Others have also shown that targeting of PDGFR circumvents resistance to VEGFR blockade (Erber et al., 2004) . Furthermore, in an animal pancreatic cancer model, SU5416, a VEGF receptor tyrosine kinase inhibitor, suppresses early, but not late, development of pancreatic tumors. More importantly in the same model, treatment with SU6668 (which inhibits both VEGF and PDGF receptor tyrosine kinases) induced regression of advanced pancreatic tumor at late stage of development (Bergers et al., 2003) , suggesting that the failure of anti-VEGF therapy may be due to its ability to inhibit only initiation but not maintenance of blood vessels. Further support for this suggestion comes from a very recent study where Avastin inhibited the formation of new blood vessels but was ineffective at inhibiting already established ones in an animal model where neuroblastoma cells were transplanted onto mouse kidneys (Huang et al., 2003) . Taken together, our present understanding of the angiogenesis process suggests that simultaneous targeting of growth factors that initiate (i.e. VEGF) as well as those that maintain (i.e. PDGF) blood vessels may be a more effective approach to cancer therapy than targeting only one growth factor.
We have taken a novel approach to this problem by designing a synthetic molecule, GFB-204, that targets both VEGF and PDGF and inhibits their binding to their respective cell surface receptors. We found GFB-204 to be a potent and selective inhibitor of VEGF and PDGF stimulation of their receptor tyrosine kinase phosphorylation and signaling (Erk1/2, Akt and STAT3). This pharmacological agent also potently inhibited endothelial cell migration and capillary network formation in vitro as well as in vivo blood vessel formation and human tumor growth in nude mouse xenografts.
Results
Identification of GFB-204, a calixarene derivative that potently inhibits VEGF and PDGF stimulation of Flk-1 and PDGF receptor tyrosine phosphorylation Our initial approach to disrupt biologically significant protein-protein interactions, such as those involving growth factors with their receptors, consisted of designing molecules that contained four synthetic peptide loops attached to a calix[4]arene scaffold ( Figure 1A(a) ) (Blaskovich et al., 2000) . The peptide loop components were based on a cyclic hexapeptide in which two residues are replaced by the dipeptide mimetic 3-aminomethylbenzoate modified with a 5-amino group to provide linkage to the calixarene cavity. This design allowed us to synthesize a library of calixarene derivatives having different peptide sequences in the loops and large surface areas capable of binding protein surfaces. One of the library members, GFB-111, bound PDGF and blocked its binding to PDGFR at sub-mM concentrations and selectively relative to other growth factors (Blaskovich et al., 2000) . The four peptide loops in GFB-111 contained negative and hydrophobic residues in the sequence GDGY ( Figure 1A(a) ), which match well with the positive and hydrophobic amino acids in loops I, II and III of the homodimeric PDGF, which are critical for binding to PDGFR (Oefner et al., 1992; Andersson et al., 1995) . A drawback of this design, however, is that the molecules are large, challenging to synthesize and present a tendency to aggregate in water. In addition, we did not identify, from the calixarene loop library, molecules with the potential antiangiogenic property of targeting both PDGF and VEGF. To address these problems, we designed a second-generation library in which, in place of the peptide loops, simple, acyclic isophthalic acid groups functionalized with a wide range of acidic and hydrophobic substituents (R 1 and R 2 , Figure 1A (b) and (VEGF) . All the library members having at least four carboxylic groups inhibited PDGF signaling at low mM concentrations (IC 50 p6 mM), while the only compound lacking acidic groups (GFB-217) did not have a significant activity. Analysis of the data in Table 1 revealed that all the potent inhibitors (having IC 50 p0.6 mM) contain R 1 ¼ COOH and R 2 ¼ hydrophobic ester or amide. GFB-211, where R 2 ¼ benzylamide, has an activity only slightly lower (IC 50 ¼ 1.3470.32 mM) than GFB-204, while GFB-209 (R 2 ¼ methyl ester) is less potent (IC 50 ¼ 2.972.05 mM). These data suggest that the structure of the hydrophobic substituents is not crucial for PDGF signaling inhibition, as long as they are larger than a methyl group. Compounds having aromatic and aliphatic groups are equally active and the more stable amides have similar activity to their ester analogs. In contrast, the calixarene derivatives containing amino-acid substituents (i.e. show in general lower activity (IC 50 in the range 1-6 mM). This may be due either to a change in the ratio of ionic to hydrophobic groups on the scaffold (these derivatives have 8-16 carboxylic acids and only 0-4 hydrophobic substituents) or to a non-optimal distance between them. Moreover, the presence of acidic groups on the isophthalic spacer seems to be more important than the presence of hydrophobic substituents: GFB-201, GFB-202, GFB-203 and GFB-206, lack hydrophobic groups in the R 1 and R 2 positions but are more potent than GFB-217, which has no carboxylate groups. Possibly, the isophthalic acid groups themselves provide a hydrophobic area that interacts with the hydrophobic regions of the receptor binding domain of PDGF. Finally, it is important to note that the most active compounds in the study have one carboxylic acid and one hydrophobic group on the four isophthalic components within the scaffold consistent with our previous studies, which led to the identification of GFB-111 (Blaskovich et al., 2000) . SAR studies also revealed that the characteristics necessary in this series for inhibition of VEGF-stimulated Flk-1 tyrosine phosphorylation are much more stringent. Indeed, besides GFB-204 I-EGF (50 000 c.p.m./well), respectively, along with increasing concentrations of GFB-204. Cells were incubated at 41C for 0.5 h, and then washed three times with PBS and three times with lysis buffer prior to determining 125 I counts as described under Materials and methods. An excess of cold VEGF, PDGF and EGF was used to obtain nonspecific binding levels Blocking angiogenesis by inhibiting VEGF and PDGF receptor binding J Sun et al Figure 1C ). In contrast, processed for antiphosphotyrosine (PDGF and VEGF) and for antiphospho-Erk1/2, Akt and STAT3 (PDGF, VEGF, EGF, bFGF and IGF-1) Western immunoblotting as described under Materials and methods. Figure 2a shows that, as described in Table 1 (Figure 2b ).
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GFB-204 inhibits angiogenesis in vitro and in vivo and suppresses the growth of human tumors in nude mice
The ability of GFB-204 to inhibit potently and selectively PDGF/ and VEGF/ligand receptor binding and subsequent signaling prompted us to determine whether this agent could inhibit angiogenesis in vitro and in vivo and, subsequently, inhibit tumor growth. We first determined if GFB-204 could inhibit angiogenesis in vitro by evaluating its ability to suppress VEGF-induced human brain endothelial capillary network formation as described under Materials and methods. GFB-204 was highly efficient at inhibiting VEGF-induced capillary network formation with an IC 50 value of 700 nM ( Figure 3a) . We next determined the ability of GFB-204 to inhibit human brain endothelial cell migration as , the mice were randomized and treated either with vehicle (E) or GFB-204 at 1 mg/kg (') and 5 mg/kg (), and tumor sizes measured as described under Materials and methods. (d) Tumors were processed 2 h after the last i.p. injection for CD31 IHC staining as described under Materials and methods. (d1) Control and (d2) GFB-204 (5 mpk). Quantification of microvessel density ( Â 400) was determined as described under Materials and methods and is presented as average 7 standard error described under Materials and methods. GFB-204 inhibited VEGF-induced endothelial cell migration through Matrigel pores into the lower chamber with an IC 50 value of 600 nM (Figure 3b ). GFB-204 had no effect on unstimulated cells (data not shown).
The ability of GFB-204 to inhibit VEGF and PDGF binding to their receptors and subsequent signaling coupled with its ability to inhibit VEGF-induced endothelial cell migration and capillary network formation suggested that GFB-204 might inhibit angiogenesis and tumorigenesis in whole animals. We, therefore, evaluated next whether GFB-204 is able to suppress tumor growth and angiogenesis in vivo by implanting human lung cancer A-549 cells subcutaneously (s.c.) in nude mice. When tumors reached an average size of 100 mm 3 , the mice were treated with either vehicle or GFB-204 and, 3 weeks later, the tumors were removed and processed for CD31 immunostaining to determine GFB-204 antiangiogenic effects as described under Materials and methods. Tumors from control animals grew to an average size of 7497111 mm 3 (Figure 3c ). In contrast, tumors from GFB-204-treated animals grew to an average size of only 6507114 mm 3 (GFB-204; 1 mg/kg) and 2847108 mm 3 (GFB-204; 5 mg/kg), respectively. Thus, treatment with GFB-204 resulted in a statistically significant (Po0.05) tumor growth inhibition at 5 mg/kg (73%) but not at 1 mg/kg (15%). Tumor sections from GFB-204-treated animals show a significant inhibition of CD31 staining (Figure 3d ). Quantification of microvessels at field magnification ( Â 400) indicated that tumors from vehicle-treated mice contained 11.371.9 microvessels, whereas those from mice treated with GFB-204 (5 mg/kg) had only 2.670.9 microvessels. Taken together, the results clearly demonstrated that GFB-204 inhibits A-549 xenograft tumor growth and angiogenesis in vivo. GFB-204 had no effect on total body weight or organ weight and necropsy results showed no organ histopathological abnormalities (data not shown).
Discussion
The strict requirement and stringent dependence of tumor growth on angiogenesis has prompted many investigators to design strategies for cancer therapy by disrupting angiogenesis resulting in deprivation of cancer cells of nutrients and essentially tumor starvation (Relf et al., 1997; Blaskovich et al., 2000; Laird et al., 2000; Morin, 2000; Wedge et al., 2000; Ferrara, 2002a; Jain, 2002; Miao et al., 2002; Zhang et al., 2002; Huang et al., 2003) . Although targeting angiogenesis as an approach to cancer therapy was suggested decades ago, it is only very recently that the first drug designed to target a step in the complex process of angiogenesis has been approved by the FDA (Ferrara, 2002a) . Indeed, Avastin, a humanized anti-VEGF monoclonal antibody, has shown activity against metastatic colon cancer. Although pivotal for providing proof of concept for targeting angiogenesis in humans, this approach has not been fully exploited. One improvement would be to design strategies that simultaneously target different steps in the angiogenic process (Relf et al., 1997; Bergers et al., 2003; Huang et al., 2003) . In this manuscript, we report a novel synthetic pharmacological agent that inhibits the function of both VEGF and PDGF, growth factors that have been shown to mediate initiation and maintenance of new blood vessels, respectively (Dvorak et al., 1999; Eriksson and Alitalo, 1999; Ferrara, 1999; Dvorak, 2002; Bergers et al., 2003) . This is the first report of an agent that binds both PDGF and VEGF and that inhibits the binding of both growth factors to their receptors and subsequently suppresses tyrosine phosphorylation and downstream signaling pathways (Erk, Akt and STAT3). GFB-204 also blocked potently the ability of endothelial cells to migrate (IC 50 ¼ 600 nM) as well as their ability to form capillaries in vitro (IC 50 ¼ 700 nM). In vivo, treatment of mice bearing human tumors s.c. led to inhibition of blood vessel formation around the tumor mass as well as inhibition of tumor growth. Although GFB-204 potently inhibited both VEGF and PDGF binding to their receptors (200-500 nM), it was not a nonspecific disrupter of all of ligand/receptor binding since EGF binding to its receptor was not affected at doses as high as 100 mM. Further support for selectivity was provided by demonstrating that GFB-204 inhibited the activation of Erk1, Erk2, Akt and STAT3 by PDGF and VEGF but not by EGF, bFGF or IGF-1.
Identification of calix[4]arene derivatives capable of blocking binding of both VEGF and PDGF to their receptors is an entirely novel approach to targeting receptor tyrosine kinase signaling. Although the anti-VEGF antibody Avastin also blocks VEGF binding to its receptor (Ferrara, 2002a; Zhang et al., 2002) , to our knowledge there are no other agents that block binding of both PDGF and VEGF to their receptors. Furthermore, the advantage of GFB-204 over Avastin is that GFB-204 is a much smaller molecule that can be easily synthesized at low cost, unlike the laborious and expensive methods involved in generating antibodies for therapeutic purposes. Although prior to this report there were no dual inhibitors of VEGF and PDGF binding to their receptors, dual inhibitors of VEGF and PDGF receptor tyrosine kinases have been made and some are in clinical trials (Kerbel, 2000; Laird et al., 2000; Morin, 2000; Wedge et al., 2000; Jain, 2002; Miao et al., 2002) . There are distinct differences between these ATP mimics and GFB-204. While the target for GFB-204 is the ligand/receptor interaction that occurs on the outer cell surface, ATP mimics target the tyrosine kinase domains of the receptors that are intracellular. Therefore, unlike GFB-204, kinase inhibitors must enter cells to reach their target. Furthermore, most tyrosine kinase inhibitors target the ATP binding site, variations of which are ubiquitous in cells. Therefore, the outcome of treating patients with GFB-204 may be very different from that of treating patients with an ATP mimic that targets both PDGF and VEGF receptor tyrosine kinases. Advanced preclinical studies are underway in preparation for an IND application for phase I testing of GFB-204 in humans.
Materials and methods
Synthesis of GFBs
Full details of the synthetic routes to these growth factor binding agents will be published elsewhere.
Inhibition of growth factor-dependent receptor tyrosine phosphorylation by GFBs
Starved Flk-1/KDR-overexpressing NIH 3T3 cells (Flk-1/NIH 3T3) or NIH 3T3 cells were pretreated with GFBs for 5 min before stimulation with VEGF (50 ng/ml) or PDGF-BB (10 ng/ ml) for 10 min, respectively. The cells were then harvested and lysed, and proteins from the lysates were separated by SDS-PAGE and transferred to nitrocellulose. Membranes then were either immunoblotted with anti-phospho-VEGFR2 antibody (Cell Signaling Technologies, Beverly, MA, USA) for activated Flk-1 or anti-phospho-tyrosine antibody (4G10, Upstate Biotechnology, Lake Placid, NY, USA) for activated PDGFR as described by us (Blaskovich et al., 2000) . Phosphotyrosine Flk-1 and PDGFR were quantified using a Bio-Rad Model GS-700 Imaging Densitometer (Bio-Rad Laboratories Inc., Hercules, CA, USA).
Growth factor-mediated stimulation of phosphorylation of Erk1/2, Akt and STAT3
Starved NIH 3T3 cells (PDGF-BB, bFGF) and NIH 3T3 cells overexpressing EGFR (EGFR/NIH 3T3, EGF), Flk-1 (Flk-1/ NIH 3T3, VEGF) and IGF-1R NIH 3T3 (IGF-1R/NIH 3T3, IGF-1) were pretreated with the indicated concentration of GFB-204 for 5 min before 10 min stimulation with PDGF-BB (10 ng/ml), EGF (100 ng/ml), bFGF (50 ng/ml), VEGF (50 ng/ ml) and IGF-1 (50 ng/ml). Cell lysates were run on SDS-PAGE gels, and then transferred to nitrocellulose and Western blotted with anti-phosphorylated Erk1/Erk2 (Cell Signaling Technologies), anti-phosphorylated Akt or anti-phosphorylated STAT3 as described previously by us (Blaskovich et al., 2003) .
Fluorescence titration assays for PDGF and VEGF binding to GFB-204
The ability of GFB-204 to interact with PDGF and VEGF was determined by fluorescence titration assays. PDGF contains a single tryptophan, which was excited at 295 nm to fluoresce at 335 nm. VEGF contains four tryptophans that were excited at 288 nm to fluoresce at 335 nm. Tryptophan fluorescence measurements were carried out using the Bio-Tek fluorometer (Winooski, VT, USA). Increasing concentrations of GFB-204 (0-3000 nM) were added to PDGF (250 nM) or VEGF (250 nM) in PBS (pH 7.2) as the binding buffer. All data were collected at 251C. I-EGF to their respective receptors was carried out as described previously (Blaskovich et al., 2000) . Briefly, Flk-1/NIH 3T3 cells, NIH 3T3 cells and EGFR/NIH 3T3 cells were incubated with ). An excess of cold growth factors were used to obtain nonspecific binding levels.
Capillary network formation
A measure of 200 ml of Matrigel was placed into each well of a 24-well culture plate at 41C and allowed to polymerize by incubation at 371C as described previously (Papadimitriou et al., 2001) . Human middle cerebral artery endothelial cells (5 Â 10 4 ) (Paris et al., 2004) were seeded on the Matrigel in 1 ml of EBM containing VEGF (20 ng/ml). The cells were incubated in the presence or absence of GFB-204 at the concentrations indicated in the figure legend. Each sample was photographed using a Â 10 objective lens, and quantified the total length of tube structures in each photograph using the Image Pro Plus software (Media Cybernetic Inc., MD, USA).
Human brain endothelial cell migration assay
Migration of adult human brain endothelial cells was evaluated using a modified Boyden chamber assay (BD BioCoat Matrigel Invasion Chamber) (Papadimitriou et al., 2001) . The cells were plated at 4 Â 10 4 /ml onto an 8 mm pore size membrane coated with a thin layer of Matrigel basement membrane matrix. GFB-204 was added to the medium in the outer chamber and the cells were cultured for 18 h under VEGF-dependent condition in the lower chamber (VEGF 20 ng/ml). Noninvading cells were removed from the upper surface with a cotton swab. Membrane inserts were then fixed with 4% paraformaldehyde and stained with Crystal-Violet dye. The number of cells that migrated to the undersurface of the filters was quantified by counting the cells migrated in randomly selected microscopic fields ( Â 10). Samples were analysed for significant differences using a Student's t-test for independent samples.
Antitumor activity in the nude mouse tumor xenograft model Nude mice (Charles River, Wilmington, MA, USA) were maintained in accordance with the Institutional Animal Care and Use Committee (IACUC) procedures and guidelines. A-549 cells were harvested and resuspended in PBS, and then injected s.c. into the right and left flanks (10 Â 10 6 cells per flank) of 8-week-old female nude mice as reported previously (Sun et al., 1999) . When tumors reached about 100 mm 3 , animals were dosed intraperitoneally (i.p.) with 0.2 ml solution once daily. Control animals received a vehicle, whereas treated animals were injected with GFB-204 (1 or 5 mg/kg/day). The tumor volumes were determined by measuring the length (l) and the width (w) and calculating the volume (V ¼ lw 2 /2) as described previously (Sun et al., 1999) . Statistical significance between control and treated animals were evaluated using Student's t-test.
IHC study
On the termination day of antitumor experiments, the tumors were extracted and fixed in 10% neutral-buffered formalin for 6 h. After fixation, the tissue samples were processed into paraffin blocks. Tissue sections (4 mm thick) were obtained from the paraffin blocks and stained with hematoxylin and eosin (H&E) using standard histological techniques. Tissue sections were also subjected to immunostaining for CD31 (BD Biosciences, San Diego, CA, USA) using the avidin-biotin peroxidase complex technique (Blaskovich et al., 2000) . Mouse monoclonal antibody was used at 1 : 50 dilution following microwave antigen retrieval (four cycles of 5 min each on high in 0.1 M citrate buffer).
